Then, we validated causal relationships between miR-106-5p and its predicted targets in vitro, and showed that miR-106-5p decreased cell invasiveness in vitro, which may contribute better prognosis for p53-like bladder cancer patients with higher miR-106-5p activity (Fig. 3b and Fig. 4a). Here, TP53 is linked to urinary bladder carcinoma.